Kiniksa Pharmaceuticals International
🇧🇲Bermuda
- Country
- 🇧🇲Bermuda
- Ownership
- -
- Employees
- 297
- Market Cap
- $1.9B
- Introduction
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading
20+ companies, including Regeneron and Sanofi, are advancing 25+ urticaria drugs through clinical trials, addressing unmet needs in treatment.
© Copyright 2024. All Rights Reserved by MedPath